Pharmacokinetic Study of Tesmilifene (YMB1002) Plus Epirubicin and Cyclophosphamide in Metastatic Breast Cancer
Status:
Completed
Trial end date:
2006-01-01
Target enrollment:
Participant gender:
Summary
This is a Phase I, multi-centre, open-label, cross-over pharmacokinetic study designed to
investigate whether the co-administration of a fixed dose of tesmilifene alters the plasma
pharmacokinetics of a standard regimen of epirubicin and/or its principle metabolite,
epirubicinol and cyclophosphamide.